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This review evaluates the safety of echinacea and elderberry in pregnancy. Both herbs
are commonly used to prevent or treat upper respiratory tract infections (URTIs) and
surveys have shown that they are also used by pregnant women. The electronic databases
PubMed, ISI Web of Science, AMED, EMBASE, Natural Medicines Comprehensive
Database, and Cochrane Library were searched from inception to November 2013.
Relevant references from the acquired articles were included. No clinical trials concerning
safety of either herb in pregnancy were identified. One prospective human study and two
small animal studies of safety of echinacea in pregnancy were identified. No animal- or
human studies of safety of elderberry in pregnancy were identified. Twenty clinical trials
concerning efficacy of various echinacea preparations in various groups of the population
were identified between 1995 and 2013. Three clinical trials concerning efficacy of two
different elderberry preparations were identified between 1995 and 2013. The results
from the human and animal studies of Echinacea sp. are not sufficient to conclude on
the safety in pregnancy. The prospective, controlled study in humans found no increase
in risk of major malformations. The efficacy of Echinacea sp. is dubious based on the
identified studies. Over 2000 persons were given the treatment, but equal amounts of
studies of good quality found positive and negative results. All three clinical trials of
Elderberry concluded that it is effective against influenza, but only 77 persons were given
the treatment. Due to lack of evidence of efficacy and safety, health care personnel should
not advice pregnant women to use echinacea or elderberry against upper respiratory tract
infection.
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INTRODUCTION
This review considers two herbal treatments against upper res-
piratory tract infection (URTI); Echinacea sp. and Sambucus
nigra and the safety of their use by pregnant women. Echinacea
sp. are commonly used by pregnant women (Hepner et al.,
2002; Nordeng and Havnen, 2004; Holst et al., 2009a; Heitmann
et al., 2010), but documentation of safety in pregnancy is
sparse. Sambucus nigra is used by pregnant women in Norway
(Nordeng and Havnen, 2004) and the USA (Tsui et al., 2001)
while no documentation of use in other regions is available to
our knowledge. The use of herbal remedies among pregnant
women in the western world is common though the documen-
tation of safety and efficacy is lacking (Nordeng and Havnen,
2004; Forster et al., 2006; Lapi et al., 2008; Holst et al., 2009a;
Cuzzolin et al., 2010; Facchinetti et al., 2012). Clinical trials of
herbs are not common and for ethical reasons pregnant women
are so far only included in trials of herbs against pregnancy-
specific conditions like nausea and vomiting (NVP) (Pongrojpaw
et al., 2007; Ensiyeh and Sakineh, 2008; Ozgoli et al., 2009).
Still pregnant women use herbs against many other conditions
(Nordeng and Havnen, 2004; Holst et al., 2009a; Heitmann et al.,
2010).
Pharmaceuticals are generally not tested in pregnant women,
but the drug substances are tested for their teratogenic poten-
tial in two animal species before they are approved for human
use. Whether this gives a good prediction of teratogenic poten-
tial in humans, is controversial, but in many cases it gives an
indication to be followed up by pharmacovigilance (Koren and
Nordeng, 2013). New teratogenic effects are often first reported
as case reports. These can be followed by observational stud-
ies of exposed pregnant women compared to healthy pregnant
controls or disease matched women. Linking of various reg-
istries like a prescription registry with the medical birth registry
can give us important information about teratogenicity of phar-
maceuticals. Herbal remedies are not prescribed and their use
is therefore not registered. Only the user has the information
and if she is not asked by health care personnel in antenatal
care or does not reveal her herb use, no link between herbs
and pregnancy outcome can be made. In large observational
studies like the Norwegian Mother and Child Cohort study
(Norwegian Institute of Public Health, 2007) the safety of com-
monly used herbs can be studied (Heitmann et al., 2013), but
even studies like that of more than 100.000 pregnancies may
be limited by study power if the frequency of herbal use is
www.frontiersin.org March 2014 | Volume 5 | Article 31 | 1
Holst et al. Echinacea and elderberry
low as malformations rarely occur and most teratogens cause
only a moderate rise in risk. Heitmann et al. (2013) found
that their study had ≥80% statistical power to rule out a dou-
bling or more of the risk of major malformations after con-
sumption of ginger (n = 466 in the first trimester) during early
pregnancy.
Herbs can pose various risks in pregnancy (Schaefer et al.,
2007). Some herbs like black cohosh (Actaea racemosa L.) or blue
cohosh (Caulophyllum thalictroides (L.) Michaux) have tradition-
ally been used to stimulate menstruation or provoke abortion.
Alkaloid-containing herbs like barberry (Berberis vulgaris L.) are
potentially hepatotoxic, but many of them are used by medi-
cal herbalists to treat conditions like constipation or heartburn.
Laxatives containing anthraquinones from for instance senna
(Senna alexandrina Mill.) or cascara (Rhamnus purshiana DC.)
are effective stimulants of the bowel peristalsis, but might the-
oretically also stimulate uterus. Some women might substitute
necessary prescribed pharmaceuticals for herbs due to a belief
in their safety and will thus not be treated properly for a
serious condition. Others might use a herbal product before
they become pregnant and just continue the use unconsciously.
Some herbal products have been found to be contaminated with
heavy metals or deliberately added pharmaceuticals and in some
cases misidentified herbs have been included (Schaefer et al.,
2007).
A benefit-risk evaluation is essential when a pregnant woman
considers using a herbal product. The fact that there is no doc-
umentation of safety does not mean that there is a risk—it just
means that we don’t know. If the benefit is substantial, it might
be reasonable to use the product in spite of the sparse safety doc-
umentation. This is commonly the case for pharmaceuticals. The
use of for instance antiepileptic drugs is essential for the mother
and although the drug may pose a risk for the fetus, the benefit
in many cases is found to outweigh the risk. As the use of herbal
products is hardly essential (at least in the western world) the risk
should preferably be documented to be minute before a product
is recommended.
Echinacea sp. used for treatment of URTI (mainly cold) are
Echinacea purpurea, Echinacea pallida, and Echinacea angustifolia.
Used plant parts are “herba” and “radix,” separately or com-
bined. The remedies are manufactured by different extraction
methods possibly leading to extraction of different constituents
and/or different amounts of the constituents. The herbal reme-
dies are sold as tablets, tincture, or tea. For those reasons it is
difficult to compare herbal remedies containing Echinacea sp. The
European Medicines Agency, EMA, has developed monographs
for Echinacea purpurea herba and radix, Echinacea pallida radix
and Echinacea angustifolia radix (European Medicines Agency,
2008, 2009, 2010, 2012). In accordance with these legal texts
none of the licensed herbal products containing Echinacea sp.
should be used during pregnancy or lactation due to lack of
sufficient data. The only exception is topical use of Echinacea
purpurea herba on other areas than the breast, this because
systemic absorption is not expected. The German commis-
sion E Monographs on the other hand state that no restric-
tions on use during pregnancy or lactation are known except
from parenteral use of Echinacea purpurea root (Blumenthal
et al., 2000), however no references to scientific papers are
given.
Sambucus nigra berry is used for treatment of URTI, mainly
the flu. The European Medicines Agency, EMA, has worked on a
monograph for the berries, but has terminated the work inMarch
2013 due to lack of information on traditional use with a speci-
fied dosage for at least 30 years (including 15 years in the EU)
(European Medicines Agency, 2013a,b). Due to lack of informa-
tion they do not recommend use of the berries during pregnancy
or lactation.
Importantly, many trademark products containing echinacea
or elderberry will be defined as dietary supplements and thus not
be legally bound to follow the recommendations in the official
plant monographs.
The aim of this study was to review the literature on safety
during pregnancy and efficacy against URTI of Echinacea sp.
and Sambucus nigra to help health care personnel to make
evidence based decisions about their recommendations and
advice.
MATERIALS AND METHODS
DATA SOURCES
The electronic databases PubMed, ISI Web of Science, AMED,
EMBASE, Natural Medicines Comprehensive Database, and
Cochrane Library were searched from inception to November
2013 and relevant references from the acquired articles were also
included. The applied search words/terms were:
A. Safety/reproductive toxicology AND pregnant/pregnancy
AND Echinacea/coneflower
B. Safety/reproductive toxicology AND pregnant/pregnancy
AND Sambucus nigra/elderberry
C. Efficacy AND Echinacea/coneflower
D. Efficacy AND Sambucus nigra /elderberry
Echinacea sp. covers Echinacea purpurea, Echinacea pallida, and
Echinacea angustifolia.
DATA EXTRACTION
Acquired references were handled according to PRISMA 2009
flow diagram (Moher et al., 2009). This states four steps:
(1) Identification: number of records identified through database
searching and number of additional records identified
through other sources
(2) Screening: number of records after duplicates removed lead-
ing to number of records screened again leading to number
of records excluded and
(3) Eligibility: number of full text articles assessed for eligibility
leading to number of full text articles excluded (with reason)
and
(4) Included: number of studies included in the qualitative syn-
thesis leading to number of studies included in the quantita-
tive synthesis
This analysis was performed for the searches A–D separately.
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STUDY SELECTION
Articles excluded:
• other languages than English and the Scandinavian languages
• multi-herbal products
• in vitro studies
• other diagnoses than cold/flu (with respect to efficacy)
• Articles more than 20 years old (from 2013)
• Articles reporting prevalence of drug use
• Reviews
• Conference abstracts, letters, notes, editorials
The quality of the studies was evaluated according to criteria from
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins and Green, 2011).
RESULTS
The studies revealed in the literature searches and the selection of
studies for the review is illustrated in Figure 1.
ECHINACEA SP.
The only available human data on safety of echinacea in
pregnancy come from one study of 412 pregnant women
whereof 206 had used echinacea as tablets or tincture in var-
ious doses and with the most common duration being 5–7
days (Gallo et al., 2000). This cohort was disease-matched
to women exposed to non-teratogenic agents by maternal
age, alcohol intake and smoking, and rates of major and
minor malformations were compared. No statistically signifi-
cant differences were found between the groups with respect
to pregnancy outcome, delivery method, maternal weight gain,
gestational age, birth weight, fetal distress, or major malforma-
tions. See Table 1. No case reports describing side effects were
located.
Two animal studies on reproductivity are also available (Chow
et al., 2006; Barcz et al., 2007). See Table 1.
Twenty studies of the efficacy of Echinacea sp. against URTI
were identified; see Table 2 (Dorn et al., 1997; Hoheisel et al.,
1997; Melchart et al., 1998; Brinkeborn et al., 1999; Grimm
and Muller, 1999; Lindenmuth and Lindenmuth, 2000; Turner
FIGURE 1 | Identification of the studies included in the review.
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Table 1 | Clinical trials and other human and animal studies of safety of Echinacea sp. in pregnancy.
Author and year of
publication
Description Conclusion
Echinacea sp. (Echinacea purpurea, pallida, and/or angustifolia. Products have various combinations of those three herbs or just one or two.)
Gallo et al. (2000)
Prospective study
HUMAN
Doses: Tablets 250–1000mg/day Tincture 5–30 drops/day
Duration: most commonly 5–7 days
Participants (treatment:control): 206:206
No statistically significant difference in terms of pregnancy
outcome (gestational age, birth weight, fetal distress or minor or
major malformations), delivery method or maternal weight gain
Chow et al. (2006)
ANIMAL
Doses: 0.45mg/day/body weight
Six pregnant mice were given a controlled diet with
echinacea and seven were given a diet without
Eight non-pregnant mice were given a diet without
Three mice from each group were euthanized at the
gestational ages 10–11 and 12–14 days. Fetal status
(dead/alive) and number was registered. Number of
hemopoietic cells from spleen and bone marrow from the
pregnant mice was counted
Cell types (splenic lymphocytes and nucleated erythroid cells)
normally increased during pregnancy were significantly reduced
in E. purpurea-consuming mice to the level of non-pregnant
mice. Bone marrow was not influenced by E. purpurea
Increased risk of early fetal resorption. Fetal resorption was
seen as pregnant mice on diet without E. purpurea had a mean
of 4.7 fetuses at 10–11 days and 4.0 at 12–14 days while mice
on diet with E. purpurea had 4.0 and 2.0, respectively
The authors argue that extrapolation to humans may not be
unreasonable and indicate that E. purpurea can cause
spontaneous abortion
Barcz et al. (2007)
ANIMAL
Eight pregnant mice were given one of three different
brands of E. purpurea tablets dissolved in water
0.6mg/day/body weight; four mice were give water as
controls from day 1 in pregnancy. Euthanized on the 18th
day of pregnancy, embryos extracted and weighted.
Embryos from one litter homogenized for testing for
angiogenesis and cytokine levels
The various E. purpurea products gave contradictive results with
respect to angiogenesis. Cytokine level was lower in all treated
animals than in controls. Number of fetuses in one litter was
slightly (but not significantly) lower after treatment with two of
the three E. purpurea products compared to the third and
control. The authors found that E. purpurea may influence fetal
angiogenesis in mice and thus should not be recommended to
pregnant women
et al., 2000; Schulten et al., 2001; Barrett et al., 2002, 2010;
Schwarz et al., 2002; Goel et al., 2004, 2005; Sperber et al.,
2004; Yale and Liu, 2004; Turner et al., 2005; Schoop et al.,
2006; Hall et al., 2007; O’Neil et al., 2008; Jawad et al., 2012).
Doses are difficult to compare as the formulations vary and are
described in mg root/herb, mg extract or as “a standardized for-
mulation.” One study included only men (Schwarz et al., 2002)
and 12 studies specifically excluded pregnant women (Hoheisel
et al., 1997; Melchart et al., 1998; Grimm and Muller, 1999;
Lindenmuth and Lindenmuth, 2000; Schulten et al., 2001; Barrett
et al., 2002, 2010; Goel et al., 2004; Sperber et al., 2004; Yale
and Liu, 2004; O’Neil et al., 2008; Jawad et al., 2012). One
study was open (Schoop et al., 2006), 19 were randomized, con-
trolled trials (Dorn et al., 1997; Hoheisel et al., 1997; Melchart
et al., 1998; Brinkeborn et al., 1999; Grimm and Muller, 1999;
Lindenmuth and Lindenmuth, 2000; Turner et al., 2000, 2005;
Schulten et al., 2001; Barrett et al., 2002, 2010; Schwarz et al.,
2002; Goel et al., 2004, 2005; Sperber et al., 2004; Yale and Liu,
2004; Hall et al., 2007; O’Neil et al., 2008; Jawad et al., 2012).
Twelve studies considered treatment of URTI (Dorn et al., 1997;
Hoheisel et al., 1997; Brinkeborn et al., 1999; Lindenmuth and
Lindenmuth, 2000; Schulten et al., 2001; Barrett et al., 2002,
2010; Goel et al., 2004, 2005; Sperber et al., 2004; Yale and
Liu, 2004; O’Neil et al., 2008); one considered only prophy-
laxis (Schwarz et al., 2002) and seven considered both aspects
(Melchart et al., 1998; Grimm and Muller, 1999; Turner et al.,
2000, 2005; Schoop et al., 2006; Hall et al., 2007; Jawad et al.,
2012). Three studies used viral challenge (Turner et al., 2000,
2005; Sperber et al., 2004) while the rest studied naturally occur-
ring disease.
Evaluation of the quality of the studies is given in Table 3.
“Random sequence generation” and “Allocation concealment”
can give an indication of selection bias. Studies with minus or
question mark in those columns are at a higher risk of selection
bias than those with a plus.
The studies have evaluated the efficacy of Echinacea sp. from
one or more of the following criteria:
- Number of episodes of cold or during treatment
- Duration of illness
- Additional painkillers or other pharmaceuticals used
- “symptom score”/severity of illness
- Virus count in nasal secretion
- Infection rate after viral challenge
All criteria had approximately as many positive as negative
results, but “Infection rate after viral challenge,” described in
three studies had only negative results. It was thus not possi-
ble to find a reduction in infection rate after virus challenge in
patients taking echinacea prophylactics or for treatment of an
induced cold.
SAMBUCUS NIGRA, ELDERBERRY
Neither human nor animal studies of the safety of Sambucus
nigra in pregnancy were identified. Only three relevant studies
on the efficacy of Sambucus nigra against URTI were identified
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Table 2 | Clinical trials and other human studies on the efficacy of Echinacea sp. against upper respiratory tract infections.
References Study population
Participants completing the
study.
Given as treatment:control
where only two groups and
otherwise with letters A, B, C,
etc. referring to interventions
Intervention Comparator Outcome
Jawad et al. (2012)
UK
RCT
Healthy individuals, ≥18 years old
Participants: 673 (325:348)
Pregnant and lactating women
excluded
Echinaforce® tincture
(E. purpurea, 95% herba + 5%
radix)
Prevention: 3 × 0.9ml/day
(2400mg extract)
Treatment 5 × 0.9ml/day
(4000mg extract)
Started on preventive dose,
increased to treatment dose
when needed
Placebo In the placebo group significantly
more days where participants
experienced a cold, recurrent
infections, cold episodes treated
with pain medication and
membraneous viruses detected in
nasal secretion were registered
Barrett et al. (2010)
USA
RCT
Individuals with a cold started
within the last 36 h, ≥12 years old
Participants: 719 (A:174. B:182.
C:179. D:184)
Pregnant women excluded
E. purpurea root and
E. angustifolia root
Echinacea corresponding to 10.2 g
dried root during first 24 h, then
5.1 g each of the next 4 days
4 groups: A: no treatment, B:
placebo tablets, C: echinacea
tablets blinded, D: echinacea
tablets open-label
Placebo Mean global severity and mean
illness duration were slightly
lower for the two
echinacea-groups than for the
other two groups, but none of the
differences were statistically
significant
O’Neil et al. (2008)
USA
RCT
Convenience sample of healthy
adults working in a university
health care center, 18–65 years
old
Participants: 58 (28:30).
Pregnant and lactating women
excluded
E. purpurea 300mg capsules,
3 × 2 daily for 8 weeks
Placebo =
parsley
No significant difference in
number of days with cold
symptoms, median number of
sick days, or mild adverse effects
between the two groups
Hall et al. (2007)
USA
RCT
Healthy active adults.
Participants: 32 (18:14)
E. purpurea Nature’s Way®
capsules 2 × 4 daily
Placebo No difference was found in the
number of colds experienced, but
the echinacea-group had a
significantly shorter duration of
their cold-episodes
Schoop et al. (2006)
Switzerland
Open
Athletes recruited through GPs or
sports physicians, 18–75 years old
Participants: 80
Echinaforce forte® 750mg
(E. purpurea; 18.6mg dried plant
extracted), 95% herb + 5% radix.
1 × 2 daily for 8 weeks
None Seventy-one percent of the
participants had no cold episodes
(symptoms for more than 3 days)
during the treatment period, 26%
had 1 and 3% had 2 episodes
Turner et al. (2005)
USA
RCT
Healthy, University students
Participants: 399
(52:52:45:48:51:48:103)
E. angustifolia radix. 3 different
extracts. 1.5ml tincture (300mg
radix) × 3 daily from day −7 to
day +5, viral challenge at day 0
7 groups (3 groups given
treatment in both prophylaxis- and
treatment phase, 3 given placebo
for prophylaxis, 1 given placebo all
through)
Placebo No statistically significant effects
were detected: Prophylaxis had
no effect on the infection rate
after viral challenge. Treatment
had no effect on virus titer.
Treatment had no effect on
symptom score or on proportion
of participants with clinical cold.
No effect on course of the illness
by prophylaxis or treatment. No
effect on the amount of nasal
secretion. No effect on
inflammatory markers
(Continued)
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Table 2 | Continued
References Study population
Participants completing the
study.
Given as treatment:control
where only two groups and
otherwise with letters A, B, C,
etc. referring to interventions
Intervention Comparator Outcome
Goel et al. (2005)
Canada
RCT
Adults, 18–65 years old Recruited
via advertisements
Participants: 56 (25:31)
Echinilin® standardized
formulation of E. purpurea
(various parts) liquid formulation.
8 doses during first 24 h, 3 daily
doses for 6 days. 1 dose = 5ml.
Placebo Symptom scores were
significantly lower than day
one-level on day 4 in the
treatment group and on day 7 in
the placebo group. In the placebo
group the score was significantly
higher than day one-level on days
2–4 while in the treatment group
it never became significantly
higher
Goel et al. (2004)
Canada
RCT
Adults, 18–5 years old Recruited
via advertisements
Participants: 111 (54:57)
Pregnant and lactating women
excluded
Echinilin® standardized
formulation of E. purpurea
(various parts) liquid formulation.
10 doses during first 24 h, 4 daily
dose for 6 days
Placebo Total symptom scores were
significantly lower in the
treatment group compared to the
placebo group throughout the
study. All symptoms except
cough showed a shorter duration
in the treatment group
Sperber et al. (2004)
USA
RCT
Healthy individuals, 18–65 years
old
Participants: 46 (24:22)
Pregnant and lactating women
excluded
EchinaGuard® juice of
E. purpurea herb in ethanol,
2.5ml × 3 daily for 14 days. Virus
inoculation after 7 days
Placebo Infection rate was not decreased
by treatment with echinacea
before and after inoculation. No
significant difference between
treatment- and placebo group in
amount of persons developing a
cold. No significant difference in
daily symptom scores
Yale and Liu (2004)
USA
RCT
Patients with a cold, ≥18 years
old
Recruited via advertisements
Participants: 128 (63:65)
Pregnant and lactating women
excluded
EchinaFresh® E. purpurea herb
100mg, freeze dried juice
(capsules) × 3 daily until
symptoms relieved or up to
maximum 14 days. Treatment
started within the first 24 h of
symptoms
Placebo No statistically significant
difference in symptom scores or
time to resolution of symptoms
between the groups
Schwarz et al. (2002)
Germany
RCT
Healthy male, 20–40 years old
Participants: 40
Esberitox® E. purpurea herb
ethanol extract × 2 daily for 14
days, cross-over with placebo, 4
weeks wash-out in between
Placebo Immune stimulatory effects were
not seen after oral administration
in healthy individuals
Barrett et al. (2002)
USA
RCT
Patients with a cold, ≥18 years
old
Recruited via advertisements
Participants: 142 (69:73)
Pregnant women excluded
Capsules of 1 g dried root and
herb of E. purpurea and root of
E. angustifolia six times during
first 24 h and 3 times each
subsequent day for a maximum
of 10 days.
Placebo = alfalfa No significant difference in
severity or duration of cold
Schulten et al. (2001)
Germany
RCT
Patients with a cold, ≥18 years
old
Recruited via employer (Madaus
AG manufacturer of Echinacin®)
Participants: 70 (37:33)
Pregnant and lactating women
excluded
Echinacin®, E. purpurea herb
pressed juice, 5ml × 2 daily for
10 days
Placebo Number of days with “the
complete picture of” common
cold was significantly reduced.
The cold was experienced as
“less severe” in the treatment
group
(Continued)
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Table 2 | Continued
References Study population
Participants completing the
study.
Given as treatment:control
where only two groups and
otherwise with letters A, B, C,
etc. referring to interventions
Intervention Comparator Outcome
Lindenmuth and
Lindenmuth (2000)
USA
RCT
Patients with a cold, ≥18 years
old
Recruited among employees in a
nursing home
Participants: 95 (48:47)
Pregnant and lactating women
excluded
Echinacea Plus® herbal tea.
E. purpurea and E. angustifolia
herb + extract of E. purpurea root
corresponding to 1275mg dry
plant per teabag. Five to six cups
the first day and reducing with
one cup per day for the next 5
days
Placebo =
Eaters Digest®
tea
Treatment relieved symptoms of
cold/flu significantly more
effective than control tea. The
symptoms lasted significantly
shorter with treatment and the
treatment group experienced
significantly fewer days of
noticeable symptoms
Turner et al. (2000)
USA
RCT
Patients with a cold, ≥18 years
old
Recruited from a university
community
Participants: 92 (50:42)
E. angustifolia 300mg × 3 daily
for 14 days before virus challenge,
then same treatment for 5 days
Placebo No significant effect on either the
occurrence of infection or the
severity of illness
Brinkeborn et al. (1999)
Sweden
RCT
Healthy individuals, ≥18 years old
Recruited via advertisements
Participants: 180 (A:41. B:49.
C:44. D:46)
Pregnant and lactating women
excluded
A:Echinaforce® (6.78mg 5%
herba and 95% radix crude
extract), B:E. purpurea herba and
radix concentrate (48.27mg of
the same extract) and
C:E. purpurea radix 29.6mg crude
extract or D:placebo. 2 × 3 daily
for no more than 7 days
Placebo Echinaforce® and the herb and
root concentrate both showed
significant reductions in
“complaint index” compared to
placebo according to doctor’s
record and according to the
patient’s record
Grimm and Muller (1999)
Germany
RCT
Patients with a cold, ≥12 years
old
Recruited by GP
Participants: 101 (50:51)
Pregnant and lactating women
excluded
Echinacin-Liquidum® (fluid
extract of E. purpurea herba), 4ml
× 2 daily for 8 weeks
Placebo No significant difference in
incidence, duration or severity of
colds, and respiratory infections
Melchart et al. (1998)
Germany
RCT
Healthy individuals, ≥18 years old
Recruited via advertisements
Participants: 244 (A:84. B:85.
C:75)
Pregnant women excluded
Ethanolic extract of A:E. purpurea
root or B:E. angustifolia root or C:
placebo. 50 drops × 2 daily for 12
weeks from Monday to Friday
Placebo No significant difference in
number, severity, or duration of
upper respiratory tract infections,
quality of life, time to occurrence
of infection, or white blood cell
counts
Hoheisel et al. (1997)
Sweden
RCT
Patients with a cold, ≥18 years
old
Recruited by company physician
Participants: 120 (60:60)
Pregnant and lactating women
excluded
Echinagard® (E. purpurea) 20
drops every 2 h the first day, then
3 times daily for up to 10 days
Placebo Significantly fewer participants in
the treatment group experienced
“fully expressed symptoms of
acute respiratory infection” (a
“real” cold), but no difference
was seen in intensity of
symptoms between the groups.
Patients in treatment group
showed significantly more rapid
recovery
Dorn et al. (1997)
Germany
RCT
Patients with URTI, ≥18 years old
Recruited by GP
Participants:160 (80:80)
900mg E. pallidae radix liquid
preparation, 8–10 days
Placebo Duration of illness and symptom
scores of cold, weakness, pain in
arms and legs, and headache
were significantly reduced in the
treatment group
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Table 3 | Quality of the studies of efficacy of Echinacea sp.
Paper T/P/B1 Random sequence Allocation Blinding of Recruitment Quality Pos/neg
generation concealment patient and personnel result
Jawad et al., 2012 B + + + Advert on university
campus
High Pos
Hall et al., 2007 B + + + ? High Pos
Goel et al., 2005 T + + + Media advert High Pos
Goel et al., 2004 T + + + Media advert High Pos
Hoheisel et al., 1997 T + + + Employees at furniture
factory
High Pos
Dorn et al., 1997 T + + + GP High Pos
Barrett et al., 2010 T + + + Media advert, e-mail,
word of mouth
High Neg
O’Neil et al., 2008 T + + + Convenience sample of
employees in uni. med.
center
High Neg
Schwarz et al., 2002 P + + + ? High Neg
Barrett et al., 2002 T + + + Posters, newspapers,
e-mail
High Neg
Grimm and Muller, 1999 B + + + Patients from GP High Neg
Schulten et al., 2001 T + + + Employees at
manufacturer
Moderate Pos
Lindenmuth and
Lindenmuth, 2000
T ? ? + Employees at nursing
home
Moderate Pos
Brinkeborn et al., 1999 T + ? ? Media advert Moderate Pos
Turner et al., 2005 B ? ? + ? Moderate Neg
Schoop et al.,Open 2006 B – – – GP’s and sports
physicians
Low Pos
Sperber et al., 2004 T ? ? ? ? Low Neg
Yale and Liu, 2004 T ? ? ? Media advert Low Neg
Melchart et al., 1998 B ? ? ? Military sites and
industrial plant, posters
and info-events
Low Neg
Turner et al., 2000 B – – – ? Low Neg
Openopen study. Others are RCT.
1Treatment, prevention, both.
?, unclear.
(Zakay-Rones et al., 1995, 2004; Kong, 2009). All were random-
ized, controlled trials of various sizes; between 15 and 32 persons
were treated with S. nigra. See Table 4.
Evaluation of the quality of the studies is given in Table 5. One
study was slightly unclear about recruitment. In conclusion all
studies are small, but apparently well conducted.
The studies have evaluated efficacy from one or more of the
following criteria:
- Relief of symptoms
- Duration of illness
- Additional painkillers or other pharmaceuticals used
- Duration of fever
- Serological analyses/virus isolation
All three studies gave a positive result of the use of S. nigra against
URTI, in the form of faster recovery.
DISCUSSION
The results from the human and animal studies of Echinacea sp.
are not sufficient to conclude on the safety in pregnancy. The
human study (Gallo et al., 2000) was prospective with respect to
time of birth but the women had used various echinacea prepa-
rations in various doses for various durations. The preparations
might contain any or all of the three most common Echinacea
species. It is reassuring that no significant differences were found
between the two groups in the study with respect to the outcomes
studied, however with only 206 participants taking echinacea,
less frequent unwanted effects cannot be ruled out. Of the 206
women who had used echinacea, 112 had done so during the first
trimester.With an estimated baseline risk ofmajormalformations
of 3.5%, a study power ≥80% and an Alpha Error Level of 5%
Gallo et al. (Gallo et al., 2000) could exclude a 3.5 times increase
in baseline risk of major malformations (DSS Research, 2012).
No firm conclusions on the risk of spontaneous abortions can
be drawn from the animal studies. The extrapolation of the fetal
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Table 4 | Clinical trials and other human studies on the efficacy of Sambucus nigra against upper respiratory tract infections.
References Study population
Participants (treatment:control,
where only two groups)
completing the study
Intervention Comparator Outcome
Kong (2009)
China
RCT
Patients with flu symptoms,
16–60 years old
College students
Participants: 64 (32:32)
Pregnant and lactating women
excluded
ViraBLOC®, elderberry
extract 175mg as
slow-dissolve lozenges;
× 4 daily for 2 days
Placebo No difference between symptom
scores (fever, headache, muscle
aches, cough, mucus discharge,
and nasal congestion) in
treatment and control group at
onset of treatment. Significant
difference for 4 out of 6 scores at
24 h and for all six at 48 h.
Improvement in treatment group
and worsening in placebo
Zakay-Rones et al. (2004)
Norway
RCT
Patients with flu symptoms, ≥18
years old
Recruited by GP
Participants: 60 (30:30)
Pregnant and lactating women
excluded
Sambucol®, 15ml × 4
daily for 5 days
Placebo No difference between symptom
scores (aches, cough, quality of
sleep, mucus discharge, nasal
congestion, “global evaluation”)
in treatment and control group at
onset of treatment. Relief of
symptoms came significantly
faster in treatment group (day 3–4
vs. day 7–8) and significantly less
rescue-medication was used.
Zakay-Rones et al. (1995)
Israel
RCT
Patients with flu symptoms, 5–56
years old
Recruited by GP
Participants: 27 (15:12)
Sambucol® 15ml × 2
daily for 3 days for
children and 15ml × 4
daily for 3 days for adults
Placebo Persistence of fever was
significantly shorter in the
treatment group. Improvement
and complete cure took
significantly longer in the placebo
group.
Table 5 | Quality of the studies of efficacy of Sambucus nigra.
Paper T/P/B1 Random Allocation Blinding of Recruitment Quality Pos/neg
sequence generation concealment patient and personnel result
Kong, 2009 T + + + ? High Pos
Zakay-Rones et al., 2004 T + + + GP High Pos
Zakay-Rones et al., 1995 T + + + Dispensary in kibbutz High Pos
1Treatment, prevention, both.
resorption noticed in mice (Chow et al., 2006) to risk of abortion
in humans lacks further documentation and with only three mice
in the treatment and three in the control group the study gives a
very weak indication of risk. The contradictive results on angio-
genesis in only eight mice (Barcz et al., 2007) are difficult to relate
to human conditions. The authors recommend that health care
personnel omit communicating data from animal studies or other
unconfirmed hypothesis to pregnant women.
No documentation is available about the safety of use of
Sambucus nigra during pregnancy, and the extent of such use
is only reported in Norway (Nordeng and Havnen, 2004). One
study (Tsui et al., 2001) from the USA mentions use, but does not
quantify it. This apparently limited use might explain the lack of
safety data.
A case report is often the first indication of a risk, but none
were located on either of the herbs. The lack of case reports can
be due to the lack of side effects to report or because health care
personnel do not ask pregnant women about herb use (Holst
et al., 2009b) or the women do not report it and connections
are not made. It is important that doctors or midwives in the
antenatal care ask pregnant women about herb use and that they
do it in a non-judgmental way. This non-judgmental approach
is essential to get a reliable answer, and thereby acquiring more
documentation.
To do a benefit-risk evaluation of a treatment there is a need
for efficacy-data in addition to safety documentation. A method
for benefit-risk analysis evaluation is given in the ICH guideline
E2C from the EMA (European Medicines Agency, 2013c).
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The studies evaluate efficacy from different criteria making
comparison difficult. For echinacea only two criteria; “Virus
count in nasal secretion” and “Infection rate after viral challenge”
are objective. The others are according to patients’ experience.
The main findings in the studies are concerned with duration or
severity of the cold but no firm conclusions can be drawn. This
is in accordance with the latest Cochrane review last edited in
2009 (including articles up to 2005) which concludes that some
preparations based on the herb of E. purpurea might be effective
in reduction of duration and severity of a cold whereas oth-
ers do not (Linde et al., 2006). An important disadvantage of
the studies is that it is difficult to compare amounts of active
substances given in the various studies due to different ways of
defining them (see Table 2, column “Intervention”). The qual-
ity of the studies is variable (see Table 3). Schoop et al (Schoop
et al., 2006) have published an open study, so lack of randomiza-
tion is obvious, but the paper by Turner et al. from 2000 (Turner
et al., 2005) lacks the information needed to evaluate how ran-
domization and blinding is performed. Other studies are unclear
with respect to randomization or blinding or both. Schulten et al.
(2001) have performed their study with employees of the man-
ufacturer of the study product which could probably bias the
result. Of the seven studies with risk of bias, four showed neg-
ative results and three positive. The distribution of positive and
negative results are also even over time. This indicates that the
efficacy of Echinacea sp. is dubious based on the identified studies
and combined with the lack of safety documentation the conclu-
sion is that the products should not be recommended to pregnant
women.
The documentation of efficacy of Sambucus nigra is also sparse
with only three studies. The main criterion for evaluation of
efficacy in those is “Relief of symptoms” but various others
are included. Only the serological analyses or virus isolation
performed in two studies (Zakay-Rones et al., 1995, 2004) are
objective. The others are according to patients’ experience. The
three studies all conclude that the use of Sambucus nigra will lead
to faster recovery from influenza. However, only 77 patients were
given the treatment, therefore no firm conclusions can be drawn
about efficacy. As there is also a lack of safety documentation
Sambucus nigra should not be recommended to pregnant women.
It is possible that more studies on efficacy of Echinacea sp. are
available in German or French but this review has only taken into
consideration studies published in English or in Scandinavian
languages (none found). This may be a limitation but there
are good reasons to believe that if positive results were discov-
ered, they would be published in English to reach as wide an
audience as possible. Of note, we did not have access to the
trademark-products used in the studies included in this review
and consequently could not evaluate their legal status and their
compliment with the official plant monographs (Blumenthal
et al., 2000; EuropeanMedicines Agency, 2008, 2009, 2010, 2012).
CONCLUSION
Documentation of efficacy against URTI and safety in pregnancy
is insufficient to permit a benefit-risk evaluation of Echinacea sp.
or Sambucus nigra against URTI in pregnancy. Health care per-
sonnel should therefore not advice pregnant women to use those
herbs. The lack of data is not in itself an indication of a substan-
tial risk to the fetus. Women who have already used the herbs in
pregnancy should be told that the recommendation not to use the
herbs is given due to lack of safety data, and not due to data show-
ing adverse effects during pregnancy. This is important to avoid
unnecessary anxiety.
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